BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Gets Price Target Reduction from JPMorgan Chase & Co.

Posted by Stanley Muller on Nov 7th, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price target decreased by JPMorgan Chase & Co. from $87.00 to $86.00 in a research report report published on Wednesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

A number of other brokerages also recently commented on BMRN. Morgan Stanley lowered their target price on BioMarin Pharmaceutical from $122.00 to $119.00 and set an “overweight” rating on the stock in a research note on Tuesday. UBS Group initiated coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, October 15th. They set a “buy” rating and a $88.00 price objective on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $60.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday. BMO Capital Markets reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Finally, William Blair raised shares of BioMarin Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.91.

Read Our Latest Stock Report on BioMarin Pharmaceutical

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN traded down $0.09 during midday trading on Wednesday, hitting $56.03. The company’s stock had a trading volume of 2,733,184 shares, compared to its average volume of 2,575,237. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The firm has a market cap of $10.85 billion, a P/E ratio of -560.30, a P/E/G ratio of 0.63 and a beta of 0.21. The firm’s 50 day moving average is $59.69 and its 200-day moving average is $58.47.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.28. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.59%. The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.12 EPS. Equities analysts anticipate that BioMarin Pharmaceutical will post 2.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA acquired a new position in BioMarin Pharmaceutical during the second quarter worth $811,962,000. Caisse de depot et placement du Quebec purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth about $70,749,000. Bank of New York Mellon Corp acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $66,107,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $39,312,000. Finally, Palo Alto Investors LP purchased a new position in BioMarin Pharmaceutical in the 2nd quarter valued at about $39,068,500. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

(Get Free Report)

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.